Zingmet Tablet SR is a combination oral hypoglycemic agent formulated to improve glycemic control in patients with type 2 diabetes mellitus. Each sustained-release tablet contains Glimepiride 2mg, Metformin 500mg, and Pioglitazone 15mg, which act synergistically through complementary mechanisms to regulate blood glucose levels. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion. Metformin, a biguanide, primarily reduces hepatic glucose production and enhances peripheral insulin sensitivity. Pioglitazone, a thiazolidinedione, improves insulin sensitivity in adipose tissue, muscle, and the liver by activating peroxisome proliferator-activated receptor gamma (PPAR-γ). The sustained-release formulation ensures a gradual release of active ingredients, promoting better tolerability and adherence. Zingmet Tablet SR is indicated for patients inadequately controlled on diet, exercise, and monotherapy or dual therapy with these agents. It is essential to monitor blood glucose levels regularly and adjust the dosage based on therapeutic response and tolerability. Contraindications include type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and known hypersensitivity to any component. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, weight gain, and edema. Use under medical supervision is advised to optimize efficacy and minimize risks.